Scinai Immunotherapeutics (NASDAQ:SCNI) and Humacyte (NASDAQ:HUMA) Financial Review

Humacyte (NASDAQ:HUMA) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Humacyte and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Scinai Immunotherapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares Humacyte and Scinai Immunotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04 million	80.34	-$40.83 million	($0.49)	-1.20
Scinai Immunotherapeutics	$1.49 million	0.44	-$8.31 million	$8.66	0.06

Scinai Immunotherapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Humacyte and Scinai Immunotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1	1	6	0	2.62
Scinai Immunotherapeutics	1	0	0	0	1.00

Humacyte currently has a consensus price target of $4.96, indicating a potential upside of 741.40%. Given Humacyte’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Humacyte is more favorable than Scinai Immunotherapeutics.

Risk & Volatility

Humacyte has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Insider and Institutional Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Scinai Immunotherapeutics beats Humacyte on 8 of the 14 factors compared between the two stocks.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.